GlassScriptPhysician profile
Alex Zapolanski
NPI 1457320186
$14,962.41
in general payments reported to CMS, 2019-2025
11 companies · $101 in 2025
The $101 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $434 · 2021: $1,710 · 2022: $1,125 · 2023: $373 · 2024: $105 · 2025: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $580.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $579.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $11,195.33 | 2019-2025 | Sapien 3 Ultra Resilia, Mitris Resilia Mitral Valve |
| Atricure, INC. | $1,303.73 | 2019-2024 | |
| Abbott Laboratories | $970.97 | 2019-2023 | Epic |
| Medtronic, INC. | $595.51 | 2021-2022 | |
| Medtronic Vascular, INC. | $392.84 | 2019-2020 | |
| Abiomed | $326.71 | 2022 | |
| Boston Scientific Corporation | $102.90 | 2021 | |
| Getinge USA Sales, LLC | $33.32 | 2019 | |
| Davol INC. | $24.70 | 2022 | |
| Ethicon US, LLC | $16.40 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$642,799.12 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Zapolanski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.